reports
- Emira Sagaama
- Margaux van Oerle
- Stephane Houri
- Thomas Zlowodzki
CON CONTINENTAL AKTIENGESELLSCHAFT
IPS IPSOS
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
GET GETLINK SE
RNO RENAULT SA
KPN ROYAL KPN NV
ORA ORANGE SA
EO FAURECIA SA
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
TYRES NOKIAN RENKAAT OYJ
GAMA GAMMA COMMUNICATIONS
LSS LECTRA SA
HAL HAL TRUST
G ASSICURAZIONI GENERALI S.P.A.
FR VALEO SE
GEBN GEBERIT AG
VOW3 VOLKSWAGEN AG PREF
WPP WPP PLC
AMP AMPLIFON S.P.A.
NEM NEMETSCHEK SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
ELI ELIA GROUP SA/NV
CIE CIE AUTOMOTIVE S.A.
KGX KION GROUP AG
OTP OTP BANK NYRT
MELE MELEXIS NV
TIT TELECOM ITALIA S.P.A.
POST OSTERREICHISCHE POST AG
RACE FERRARI NV
IDR INDRA SISTEMAS S.A. CLASS A
BIM BIOMERIEUX SA
PIRC PIRELLI & C. S.P.A.
REY REPLY S.P.A.
VOD VODAFONE GROUP PLC
GEST GESTAMP AUTOMOCION S.A.
WAVE WAVESTONE SA
PRX PROSUS N.V. CLASS N
FDJ LA FRANCAISE DES JEUX SA
DSC1 DUTCH STAR C SHAR
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
AG1 AUTO1 GROUP
NA9 NAGARRO
UMG UNIVERSAL MUSIC GROUP NV
DSY DASSAULT SYSTEMES SA
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
ARM ARM HOLDINGS PLC
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
EXENS EXOSENS
AMS AMS-OSRAM AG
- Anthony Dick
- Emira Sagaama
- Margaux van Oerle
- Michael Foundoukidis
- Stephane Houri
- Thomas Zlowodzki
CON CONTINENTAL AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
GET GETLINK SE
RNO RENAULT SA
ORA ORANGE SA
EO FAURECIA SA
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
TYRES NOKIAN RENKAAT OYJ
HAL HAL TRUST
G ASSICURAZIONI GENERALI S.P.A.
FR VALEO SE
GEBN GEBERIT AG
VOW3 VOLKSWAGEN AG PREF
AMP AMPLIFON S.P.A.
ELI ELIA GROUP SA/NV
CIE CIE AUTOMOTIVE S.A.
KGX KION GROUP AG
OTP OTP BANK NYRT
RACE FERRARI NV
BIM BIOMERIEUX SA
PIRC PIRELLI & C. S.P.A.
GEST GESTAMP AUTOMOCION S.A.
FDJ LA FRANCAISE DES JEUX SA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
UMG UNIVERSAL MUSIC GROUP NV
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
- Oliver Metzger
- Bruno Cavalier
- Emira Sagaama
- Louis Boujard
- CFA
- Philippe Ourpatian
DHLN DHL GROUP
AXA AXA
AKRBF AKER BP ASA
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
FP TOTAL SE
UBI UBISOFT ENTERTAINMENT SA
JMT JERONIMO MARTINS SGPS S.A.
SU SCHNEIDER ELECTRIC SE
AMUN AMUNDI SA
ELE ENDESA S.A.
GEBN GEBERIT AG
ORSTED ORSTED
NXT NEXT PLC
AIR AIRBUS SE
VOW3 VOLKSWAGEN AG PREF
CAP CAPGEMINI SE
AMP AMPLIFON S.P.A.
01913 PRADA S.P.A.
REP REPSOL SA
GAS NATURGY ENERGY GROUP S.A.
ARCAD ARCADIS NV
KGX KION GROUP AG
MAP MAPFRE SA
SKF B SKF AB CLASS B
PRY PRYSMIAN S.P.A.
WLN WORLDLINE SA
INGA ING GROEP NV
ABI ANHEUSER-BUSCH INBEV SA/NV
SIE SIEMENS AG
ARGX ARGEN-X SE
STM STMICROELECTRONICS NV
KBX KNORR-BREMSE AG
STLA STELLANTIS N.V.
SHEL SHELL PLC
DSFIR KONINKLIJKE DSM N.V.
- Bruno Cavalier
- Emira Sagaama
- Louis Boujard
- CFA
- Philippe Ourpatian
DHLN DHL GROUP
AXA AXA
AKRBF AKER BP ASA
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
FP TOTAL SE
UBI UBISOFT ENTERTAINMENT SA
JMT JERONIMO MARTINS SGPS S.A.
SU SCHNEIDER ELECTRIC SE
AMUN AMUNDI SA
ELE ENDESA S.A.
GEBN GEBERIT AG
ORSTED ORSTED
NXT NEXT PLC
AIR AIRBUS SE
VOW3 VOLKSWAGEN AG PREF
CAP CAPGEMINI SE
AMP AMPLIFON S.P.A.
01913 PRADA S.P.A.
REP REPSOL SA
GAS NATURGY ENERGY GROUP S.A.
ARCAD ARCADIS NV
FDR FLUIDRA S.A.
KGX KION GROUP AG
MAP MAPFRE SA
SKF B SKF AB CLASS B
PRY PRYSMIAN S.P.A.
WLN WORLDLINE SA
INGA ING GROEP NV
ABI ANHEUSER-BUSCH INBEV SA/NV
SIE SIEMENS AG
ARGX ARGEN-X SE
STM STMICROELECTRONICS NV
KBX KNORR-BREMSE AG
STLA STELLANTIS N.V.
SHEL SHELL PLC
DSFIR KONINKLIJKE DSM N.V.
- Oliver Metzger
Amplifon : Q3 review – Slower market growth reflected in estimates
>Q3 review – Bottom line below expectations - Amplifon's Q3 revenues of € 567.6m (+6.8% y-o-y, 2%/0% vs expectations) was supported by an organic growth of 4.3%, external growth of 370bp and impacted by a forex headwind of 190bp. While Americas and APAC showed strong organic growth of 13.5% and 6.0%, respectively, the most important region Europe was up by just 1.2% organically. On the bottom line, Amplifon reported a recurring EBITDA of € 115.0m (+4.9% y-o-y, ma...
Amplifon: 1 director
A director at Amplifon sold 8,999 shares at 27.390EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
- Konrad Zomer
- Konrad Zomer
- Oliver Metzger
Amplifon : High expectations priced in, downgrade to Neutral
>Hearing aid market intact but high exposure to Europe - We regard the overall hearing aid market as intact with some underlying growth of 5% in value terms. Thereby, North America and Asia/Pacific should outperform the overall market, while we forecast growth of around 4% for Europe. While Amplifon’s performance as an acoustic retail chain is linked to the underlying markets, the high exposure towards Europe (c. two-thirds of total revenues) impacts the growth potent...
- Jerôme Bodin
IFX INFINEON TECHNOLOGIES AG
EDEN EDENRED SA
JMT JERONIMO MARTINS SGPS S.A.
VIV VIVENDI SE
TEP TELEPERFORMANCE SE
HAL HAL TRUST
AMP AMPLIFON S.P.A.
01913 PRADA S.P.A.
AENA AENA SME SA
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
TIT TELECOM ITALIA S.P.A.
IBE IBERDROLA SA
COLO B COLOPLAST A/S CLASS B
ASML ASML HOLDING NV
HFG HELLOFRESH SE
- Jerôme Bodin
IFX INFINEON TECHNOLOGIES AG
EDEN EDENRED SA
JMT JERONIMO MARTINS SGPS S.A.
VIV VIVENDI SE
TEP TELEPERFORMANCE SE
HAL HAL TRUST
AMP AMPLIFON S.P.A.
01913 PRADA S.P.A.
AENA AENA SME SA
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
TIT TELECOM ITALIA S.P.A.
IBE IBERDROLA SA
COLO B COLOPLAST A/S CLASS B
ASML ASML HOLDING NV
HFG HELLOFRESH SE
- Oliver Metzger
Amplifon : FY review – Finish as expected, new share buyback programme
>Top-line finish in 2023 as expected - Yesterday, Amplifon reported Q4 revenue of € 615.0m (+6.1% y-o-y), 0%/-1% vs ODDO BHF/consensus. Sales growth in local currencies was 11.2% (vs 10.9%/11.5% expected). Organic growth was 8.9%. Acquisitions contributed 230bp while forex accounted for a headwind of 510bp. Europe performed solidly with 5.1% growth at constant currencies (4.1% organic growth). The Americas region was up strongly by 26.1% organically and acquisitions c...
- Maissa Keskes
- Stephane Houri
- Maissa Keskes
- Stephane Houri
- Oliver Metzger
Amplifon : FY results due 7 March – Incorporating higher forex headwin...
>Strong finish of Q4, but higher forex headwind incorporated - Amplifon’s Q4 revenues of € 612m (+5.7% y-o-y) should be driven by an organic growth of 9.1%, which is pushed by a strong development in the Americas and APAC on the back of a comparatively low base. For Europe, we forecast some slower organic growth of 4.0% for the last quarter. Acquisitions contribute by 180bp to revenues, while forex is expected to create a headwind of 590bp. We incorporate the higher t...
- Oliver Metzger
Amplifon : Q3 review – Solid top line, but bottom line below expectati...
>Strong top line driven by 9% organic growth - Amplifon reported Q3 revenue of € 531.3m (+5.7% y-o-y), +3%/+1% vs ODDO BHF/consensus.Sales growth in local currencies was 11.4% (vs 8.0% expected). Organic growth was 9.0%, supported by a recovering global hearing aid market. Acquisitions contributed 240bp, while forex accounted for a headwind of 470bp. Europe performed solidly with 5.8% growth in constant currencies (5.0% organic growth). The Americas region was up...
- Oliver Metzger
Amplifon : Q2 review – unspectacular in a weaker market environment
>Outperformance of weaker market driven by Americas and APAC - Amplifon reported Q2 revenue of € 573.5m (+5.9% y-o-y), +1%/-1% vs ODDO BHF/consensus. Sales growth in local currencies was 8.8% (vs 6.5%/8.6% expected). Organic growth was 6.6%, supported by a recovering global hearing aid market. Acquisitions contributed 220bp, while forex accounted for a headwind of 280bp. Europe performed comparatively weak with 3.2% growth in constant currencies (2.2% organic growth)....
- Oliver Metzger
Amplifon : Q1 review - the usual beat, guidance with moderate upside
>Solid top line development supported by recovery of global hearing aid market - Amplifon reported Q1 revenue of € 540.3m (+9.0% y-o-y), +3%/2% vs ODDO BHF/consensus. Sales growth in local currencies was 9.3% (vs 6.3% est.). Organic growth was 7.4%, supported by a recovering global hearing aid market. Acquisitions contributed 190bp, while forex accounted for a tailwind of 30bp. Europe performed solidly, with 6% growth in constant currencies. The Americas region was u...
- Life Sciences & Chemicals Team
ODDO : Defensive growth sectors
We are publishing our first slideshow on our Life Sciences & Chemicals macropole. Our expertise integrates many sub-sectors which have been schematically separated into pharma, medtech, biotech, healthcare services and chemicals. The objective here is to review on a quarterly basis the key points of our respective sectors, by publishing both the financial and market metrics as well as the stocks that we recommend. - >Pharma’s defensive role validated thanks to a reassuring...
SOON SONOVA HOLDING AG
DSM KONINKLIJKE DSM N.V.
FME FRESENIUS MEDICAL CARE AG
CVVTF COVESTRO AG
BOI BOIRON SA
IPN IPSEN SA
WCH WACKER CHEMIE AG
ROG ROCHE HOLDING LTD
MDG1 MEDIGENE AG
NOVN NOVARTIS AG
QIA QIAGEN NV
PA8 PAION AG
SBS STRATEC SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
DEMANT DEMANT A/S
RHK RHON-KLINIKUM AG
LXS LANXESS AG
GXI GERRESHEIMER AG
ABVX ABIVAX SA
BLC BASTIDE LE CONFORT MEDICAL SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
LNA LNA SANTE SA
GBT GUERBET SA
ALCLS CELLECTIS SA
MRK MERCK KGAA
NOVO B NOVO NORDISK A/S CLASS B
ALCAR CARMAT SA
SDF K+S AG
GRF GRIFOLS S.A. CLASS A
GN GN STORE NORD A/S
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
SOLB SOLVAY SA
BAYN BAYER AG
UCB UCB S.A.
ORP ORPEA SA
SY1 SYMRISE AG
AMP AMPLIFON S.P.A.
FAE FAES FARMA S.A.
KWS KWS SAAT SE & CO KGAA
SZU SUEDZUCKER AG
GNFT GENFIT SA
EVK EVONIK INDUSTRIES AG
DIM SARTORIUS STEDIM BIOTECH SA
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
ADOC ADOCIA SA
BNR BRENNTAG SE
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
ALM ALMIRALL SA
GRF.P GRIFOLS S.A. PREF CLASS B
COPN COSMO PHARMACEUTICALS NV
AZN ASTRAZENECA PLC
ALVAL VALBIOTIS SA
VIFN VIFOR PHARMA AG
BIM BIOMERIEUX SA
ALTHX THERANEXUS SA
2HRA H&R GMBH & CO KGAA
DMP DERMAPHARM HOLDING SE
SHL SIEMENS HEALTHINEERS AG
MOR MORPHOSYS AG
MEDCL MEDINCELL SA
AKZA AKZO NOBEL N.V.
MRNA MODERNA INC.
BNTX BIONTECH SE
ZEL PHARMA MAR SA
FPE3 FUCHS PETROLUB SE
SYAB SYNLAB AG
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
GSK GSK PLC
BAI BENEVOLENTAI
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.